Artios Pharma Limited announced a clinical trial collaboration and supply agreement with GSK to evaluate alnodesertib, Artios? ATR inhibitor, in combination with risvutatug rezetecan (also referred to as Ris-Rez), GSK?s novel investigational B7-H3-targeting topoisomerase-1 (Topo-1) antibody-drug conjugate (ADC), in patients with gastrointestinal tumors. Under the terms of the agreement, GSK will sponsor and conduct the Phase 1 study and provide its B7-H3 Topo-1 ADC, while Artios will supply alnodesertib.
Each party will maintain rights to its respective products, and the agreement is mutually non-exclusive. The clinical study is expected to open by the end of the year.
